A group of autosomal recessive disorders marked by a deficiency of the hepatic enzyme PHENYLALANINE HYDROXYLASE or less frequently by reduced activity of DIHYDROPTERIDINE REDUCTASE (i.e., atypical phenylketonuria). Classical phenylketonuria is caused by a severe deficiency of phenylalanine hydroxylase and presents in infancy with developmental delay; SEIZURES; skin HYPOPIGMENTATION; ECZEMA; and demyelination in the central nervous system. (From Adams et al., Principles of Neurology, 6th ed, p952).
A condition occurring in untreated or partially treated females with PHENYLKETONURIA when they become pregnant. This may result in damages to the FETUS, including MICROCEPHALY; MENTAL RETARDATION; congenital heart disease; FETAL GROWTH RETARDATION; and CRANIOFACIAL ABNORMALITIES. (From Am J Med Genet 1997 Mar 3;69(1):89-95)
An enzyme of the oxidoreductase class that catalyzes the formation of L-TYROSINE, dihydrobiopterin, and water from L-PHENYLALANINE, tetrahydrobiopterin, and oxygen. Deficiency of this enzyme may cause PHENYLKETONURIAS and PHENYLKETONURIA, MATERNAL. EC 1.14.16.1.
An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.
A group of compounds that are derivatives of phenylpyruvic acid which has the general formula C6H5CH2COCOOH, and is a metabolite of phenylalanine. (From Dorland, 28th ed)
A natural product that has been considered as a growth factor for some insects.
The identification of selected parameters in newborn infants by various tests, examinations, or other procedures. Screening may be performed by clinical or laboratory measures. A screening test is designed to sort out healthy neonates (INFANT, NEWBORN) from those not well, but the screening test is not intended as a diagnostic device, rather instead as epidemiologic.
A species of ANABAENA that can form SPORES called akinetes.
Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.
A congenital abnormality in which the CEREBRUM is underdeveloped, the fontanels close prematurely, and, as a result, the head is small. (Desk Reference for Neuroscience, 2nd ed.)
An infant during the first month after birth.
By adjusting the quantity and quality of food intake to improve health status of an individual. This term does not include the methods of food intake (NUTRITIONAL SUPPORT).
The ability to learn and to deal with new situations and to deal effectively with tasks involving abstractions.
An enzyme that catalyzes the deamination of PHENYLALANINE to form trans-cinnamate and ammonia.
Homogentisic acid is an organic compound that is an intermediate metabolite in the catabolic pathway of tyrosine and phenylalanine, and its accumulation in the body can lead to a rare genetic disorder known as alkaptonuria.
A condition in infancy or early childhood due to an in-utero deficiency of THYROID HORMONES that can be caused by genetic or environmental factors, such as thyroid dysgenesis or HYPOTHYROIDISM in infants of mothers treated with THIOURACIL during pregnancy. Endemic cretinism is the result of iodine deficiency. Clinical symptoms include severe MENTAL RETARDATION, impaired skeletal development, short stature, and MYXEDEMA.
Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)
A diet that contains limited amounts of protein. It is prescribed in some cases to slow the progression of renal failure. (From Segen, Dictionary of Modern Medicine, 1992)
A group of inherited enzyme deficiencies which feature elevations of GALACTOSE in the blood. This condition may be associated with deficiencies of GALACTOKINASE; UDPGLUCOSE-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; or UDPGLUCOSE 4-EPIMERASE. The classic form is caused by UDPglucose-Hexose-1-Phosphate Uridylyltransferase deficiency, and presents in infancy with FAILURE TO THRIVE; VOMITING; and INTRACRANIAL HYPERTENSION. Affected individuals also may develop MENTAL RETARDATION; JAUNDICE; hepatosplenomegaly; ovarian failure (PRIMARY OVARIAN INSUFFICIENCY); and cataracts. (From Menkes, Textbook of Child Neurology, 5th ed, pp61-3)
A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.

The Resource Mothers Program for Maternal Phenylketonuria. (1/13)

OBJECTIVES: The purpose of this study was to measure the effectiveness of resource mothers in reducing adverse consequences of maternal phenylketonuria. METHODS: Nineteen pregnancies in the resource mothers group were compared with 64 pregnancies in phenylketonuric women without resource mothers. Weeks to metabolic control and offspring outcome were measured. RESULTS: Mean number of weeks to metabolic control was 8.5 (SE = 2.2) in the resource mothers group, as compared with 16.1 (SE = 1.7) in the comparison group. Infants of women in the resource mothers group had larger birth head circumferences and higher developmental quotients. CONCLUSIONS: The resource mothers program described here improves metabolic control in pregnant women with phenylketonuria.  (+info)

Effect of phenylalanine and its metabolites on the proliferation and viability of neuronal and astroglial cells: possible relevance in maternal phenylketonuria. (2/13)

Phenylketonuria is a genetic defect that, without strict dietary control, results in the accumulation of phenylalanine (Phe) in body fluids. If a low-Phe diet is not maintained during pregnancy, the offspring of phenylketonuric women are born with mental retardation and microcephaly. Primary cultures of rat cerebellar granule cells, rat cortical astrocytes, human fetal astrocytes, and human neuroblastoma (SY5Y) cells and human astrocytoma (1321N1) cells were used to test the hypothesis that the microencephaly may be a result of neuronal cell death and reduced astrocyte proliferation. Exposure to Phe or to six Phe metabolites [phenylacetic acid (PAA), phenyllactic acid, hydroxyphenylacetic acid, phenylpyruvic acid, phenylethylamine (PEA), and mandelic acid] did not result in astroglial or neuronal cell cytotoxicity. Treatment of 1321N1 cells, human fetal astrocytes, or rat astrocytes with 5 mM Phe for 24 h decreased DNA synthesis 19 +/- 4, 30 +/- 4, and 60 +/- 6%, respectively. This effect was concentration dependent, and flow cytometry revealed that Phe treatment resulted in the accumulation of cells in the G(0)/G(1) phase of the cell cycle. In addition, in 1321N1 cells, exposure to 5 mM PAA, and in rat astrocytes, exposure to 0.5 mM PEA inhibited cell proliferation 42 +/- 4 and 55 +/- 4%, respectively. These metabolites also resulted in the accumulation of cells in the G(0)/G(1) phase of the cell cycle. In human fetal astrocytes, 0.5 mM PEA and 0.5 mM PAA resulted in a 41 +/- 12 and 52 +/- 11% reduction proliferation, respectively.  (+info)

Intake of major nutrients by women in the Maternal Phenylketonuria (MPKU) Study and effects on plasma phenylalanine concentrations. (3/13)

BACKGROUND: Women with untreated phenylketonuria (PKU) often have poor reproductive outcomes. OBJECTIVE: We assessed the effects of intakes of major nutrients on plasma phenylalanine concentrations and we measured phenylalanine hydroxylase activity and phenylalanine intakes in pregnant women with PKU. DESIGN: Dietary intakes and plasma phenylalanine concentrations were compared in 4 subject groups defined on the basis of plasma phenylalanine concentrations: group 1 (n = 23), <360 micromol/L by 10 wk gestation and 120-360 micromol/L throughout the remainder of pregnancy; group 2 (n = 46), <600 micromol/L but not <360 micromol/L by 10 wk gestation and 120-600 micromol/L throughout the remainder of pregnancy; group 3 (n = 24), <600 micromol/L by 10 wk gestation but >600 micromol/L at least once thereafter; group 4 (n = 147), never <600 micromol/L. RESULTS: Except in the first trimester, mean intakes of phenylalanine, energy, and fat tended to be greater in group 1 than in the other groups. The mean protein intake of group 1 tended to be greater than that of the other groups. Intakes of protein (P < 0.0001), fat (P < 0.0001), and energy (P < 0.007) were negatively correlated with maternal plasma phenylalanine concentrations. It appeared that genotype did not affect phenylalanine tolerance. CONCLUSIONS: Maternal genotype appeared to have little influence on phenylalanine requirements during the first trimester. Early decline and maintenance of maternal plasma phenylalanine concentrations at <360 micromol/L and mean protein intake greater than the recommended dietary allowance (RDA) with mean energy intake near the RDA resulted in the best reproductive outcomes. Inadequate intakes of protein, fat, and energy may result in elevated plasma phenylalanine concentrations and may contribute to poor reproductive outcomes.  (+info)

Barriers to dietary control among pregnant women with phenylketonuria--United States, 1998-2000. (4/13)

Newborns in the United States are screened for phenylketonuria (PKU), a metabolic disorder that when left untreated is characterized by elevated blood phenylalanine (phe) levels and severe mental retardation (MR). An estimated 3,000-4,000 U.S.-born women of reproductive age with PKU have not gotten severe MR because as newborns their diets were severely restricted in the intake of protein-containing foods and were supplemented with medical foods (e.g., amino acid-modified formula and modified low-protein foods). When women with PKU do not adhere to their diet before and during pregnancy, infants born to them have a 93% risk for MR and a 72% risk for microcephaly. These risks result from the toxic effects of high maternal blood phe levels during pregnancy, not because the infant has PKU. The restricted diet, which should be maintained for life, often is discontinued during adolescence. This report describes the pregnancies of three women with PKU and underscores the importance of overcoming the barriers to maintaining the recommended dietary control of blood phe levels before and during pregnancy. For maternal PKU-associated MR to be prevented, studies are needed to determine effective approaches to overcoming barriers to dietary control.  (+info)

Maternal phenylketonuria: report from the United Kingdom Registry 1978-97. (5/13)

BACKGROUND: The effects of maternal phenylalanine on the fetus include facial dysmorphism, microcephaly, intrauterine growth retardation, developmental delay, and congenital heart disease. AIMS: To evaluate the impact of phenylalanine restricted diet in pregnant women with phenylketonuria (PKU) on their offspring. METHODS: Data on virtually all pregnancies of women with PKU in the United Kingdom between 1978 and 1997 were reported to the United Kingdom PKU Registry. The effect of the use and timing in relation to pregnancy of a phenylalanine restricted diet on birth weight, birth head circumference, the presence or absence of congenital heart disease (CHD), 4 year developmental quotient, and 8 year intelligence quotient were examined. RESULTS: A total of 228 pregnancies resulted in live births (seven twin pregnancies were excluded). In 110 (50%), diet started before conception. For this group mean (SD) birth weight was 3160 (612) g, birth head circumference 33.6 (1.9) cm, 4 year DQ 108.9 (13.2), 8 year IQ 103.4 (15.6), and incidence of CHD was 2.4%. In comparison, for those born where treatment was started during pregnancy (n = 91), birth weight was 2818 (711) g, birth head circumference 32.7 (2.0) cm, 4 year DQ 96.8 (15.0), 8 year IQ 86.5 (13.0), and incidence of CHD was 17%. Month-by-month regression analyses suggested that metabolic control by 12-16 weeks gestation had most influence on outcome. CONCLUSIONS: Many features of the maternal PKU syndrome are preventable by starting a phenylalanine restricted diet. Women with PKU and their carers must be aware of the risks and should start the diet before conception, or as soon after as possible.  (+info)

An exceptional Albanian family with seven children presenting with dysmorphic features and mental retardation: maternal phenylketonuria. (6/13)

BACKGROUND: Phenylketonuria is an inborn error of amino acid metabolism which can cause severe damage to the patient or, in the case of maternal phenylketonuria, to the foetus. The maternal phenylketonuria syndrome is caused by high blood phenylalanine concentrations during pregnancy and presents with serious foetal anomalies, especially congenital heart disease, microcephaly and mental retardation. CASE PRESENTATION: We report on an affected Albanian woman and her seven children. The mother is affected by phenylketonuria and is a compound heterozygote for two pathogenetic mutations, L48S and P281L. The diagnosis was only made in the context of her children, all of whom have at least one severe organic malformation. The first child, 17 years old, has a double-chambered right ventricle, vertebral malformations and epilepsy. She is also mentally retarded, microcephalic, exhibits facial dysmorphies and small stature. The second child, a girl 15 years of age, has severe mental retardation with microcephaly, small stature and various dysmorphic features. The next sibling, a boy, died of tetralogy of Fallot at the age of three months. He also had multiple vertebral and rib malformations. The subsequent girl, now eleven years old, has mental retardation, microcephaly and epilepsy along with facial dysmorphy, partial deafness and short stature. The eight-year-old child is slightly mentally retarded and microcephalic. A five-year-old boy was a premature, dystrophic baby and exhibits mental retardation, dysmorphic facial features, brachydactyly and clinodactyly of the fifth finger on both hands. Following a miscarriage, our index case, the youngest child at two years of age, is microcephalic and mentally retarded and shows minor facial anomalies. All children exhibit features of phenylalanine embryopathy caused by maternal phenylketonuria because the mother had not been diagnosed earlier and, therefore, never received any diet. CONCLUSION: This is the largest family suffering from maternal phenylketonuria reported in the literature. Maternal phenylketonuria remains a challenge, especially in woman from countries without a neonatal screening program. Therefore, it is mandatory to be alert for the possibility of maternal phenylketonuria syndrome in case of a child with the clinical features described here to prevent foetal damage in subsequent siblings.  (+info)

Pregnancy in phenylketonuria: dietary treatment aimed at normalising maternal plasma phenylalanine concentration. (7/13)

The transport characteristics of the placenta, which favour higher phenylalanine concentrations in the fetus than in the mother, and regression data of head circumference at birth against phenylalanine concentration at conception in maternal phenylketonuria (PKU), suggest that treatment of maternal PKU should ideally aim to maintain plasma phenylalanine concentration within the normal range throughout pregnancy. A patient with classical PKU was treated from before conception by aiming to maintain plasma phenylalanine concentration within the range 50-150 mumol/l and tyrosine within the range 60-90 mumol/l. The diet was supplemented with phenylalanine-free amino acids (100-180 g/day) and tyrosine (0-5 g/day). Plasma amino acid concentrations were monitored weekly by amino acid analyser. Dietary phenylalanine intake ranged from 6 mg/kg/day at conception to 30 mg/kg/day at delivery. Normal weight gain and fetal growth were maintained throughout the pregnancy. A normal baby was born at term with a head circumference of 35.5 cm; at 1 year of age no abnormality is detectable. These results show that with careful monitoring and compliance it is possible, and may be advisable, to maintain plasma phenylalanine concentration within the normal range in the management of PKU pregnancy.  (+info)

Factors influencing outcomes in the offspring of mothers with phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine. (8/13)

BACKGROUND: Developmental delay in the offspring of women with phenylketonuria (PKU) can be prevented by maintaining maternal blood phenylalanine (Phe) within a target range (100-250 micromol/L). OBJECTIVE: We aimed to analyze outcomes in the offspring of women with PKU during pregnancy and to identify prognostic factors. DESIGN: Occipitofrontal circumference at birth (OFC-B); developmental scores [developmental quotient (DQ) and intelligence quotient (IQ)]at 1, 4, 8, and 14 y; and the time of starting a Phe-restricted diet (before or after conception) were collected. The influence of maternal Phe concentrations during pregnancy on offspring outcomes also was assessed. RESULTS: The study included 105 children born to 67 mothers with PKU. Mean (+/-SD) OFC-B z scores did not differ between the preconception and postconception diet groups (0.42 +/- 1.24 and -0.96 +/- 1.19, respectively). DQ at 1 y and IQ at 8 y were higher in offspring from the preconception diet group than in offspring from the postconception diet group [DQ: 107 +/- 13.8 and 99.3 +/- 13.3, respectively (P = 0.014); IQ: 110.6 +/- 14.8 and 91.2 +/- 23.9, respectively (P = 0.005)]. Maternal Phe concentrations correlated negatively with DQ and IQ scores, and variations (SD) in all maternal blood Phe correlated negatively with 4-, 8-, and 14-y IQ scores (r = -0.385, -0.433, and -0.712; P = 0.002, 0.008, and 0.031, respectively), even when concentrations were consistently within the target range. CONCLUSIONS: The study suggests that women with PKU should start a Phe-restricted diet before conception. Maintenance of maternal blood Phe within the target range predicts good offspring outcomes, but variations even within that range should be avoided.  (+info)

Phenylketonurias (PKU) is a genetic disorder characterized by the body's inability to properly metabolize the amino acid phenylalanine, due to a deficiency of the enzyme phenylalanine hydroxylase. This results in a buildup of phenylalanine in the blood and other tissues, which can cause serious neurological problems if left untreated.

The condition is typically detected through newborn screening and can be managed through a strict diet that limits the intake of phenylalanine. If left untreated, PKU can lead to intellectual disability, seizures, behavioral problems, and other serious health issues. In some cases, medication or a liver transplant may also be necessary to manage the condition.

Phenylketonuria, Maternal is not a medical condition itself but rather a term that refers to the potential effects of maternal phenylketonuria (PKU) on the unborn child. PKU is a genetic disorder characterized by an inability to metabolize the amino acid phenylalanine, leading to its accumulation in the body and causing intellectual disability and other neurological problems if left untreated.

If a woman with PKU becomes pregnant and does not maintain a strict low-phenylalanine diet during pregnancy, the high levels of phenylalanine in her blood can lead to abnormal fetal development. The unborn child may develop congenital heart defects, microcephaly (abnormally small head), intrauterine growth retardation, and intellectual disability. This is known as maternal PKU syndrome or fetal PKU.

Therefore, it's crucial for women with PKU who are planning to become pregnant or are already pregnant to adhere strictly to a low-phenylalanine diet and monitor their blood phenylalanine levels regularly to minimize the risk of maternal PKU syndrome.

Phenylalanine Hydroxylase (PAH) is an enzyme that plays a crucial role in the metabolism of the essential amino acid phenylalanine. This enzyme is primarily found in the liver and is responsible for converting phenylalanine into tyrosine, another amino acid. PAH requires a cofactor called tetrahydrobiopterin (BH4) to function properly.

Defects or mutations in the gene that encodes PAH can lead to a genetic disorder known as Phenylketonuria (PKU). In PKU, the activity of PAH is significantly reduced or absent, causing an accumulation of phenylalanine in the body. If left untreated, this condition can result in severe neurological damage and intellectual disability due to the toxic effects of high phenylalanine levels on the developing brain. A strict low-phenylalanine diet and regular monitoring of blood phenylalanine levels are essential for managing PKU and preventing associated complications.

Phenylalanine is an essential amino acid, meaning it cannot be produced by the human body and must be obtained through diet or supplementation. It's one of the building blocks of proteins and is necessary for the production of various molecules in the body, such as neurotransmitters (chemical messengers in the brain).

Phenylalanine has two forms: L-phenylalanine and D-phenylalanine. L-phenylalanine is the form found in proteins and is used by the body for protein synthesis, while D-phenylalanine has limited use in humans and is not involved in protein synthesis.

Individuals with a rare genetic disorder called phenylketonuria (PKU) must follow a low-phenylalanine diet or take special medical foods because they are unable to metabolize phenylalanine properly, leading to its buildup in the body and potential neurological damage.

Phenylpyruvic acid is not a medical condition, but rather a chemical compound that is produced in the body. It is a byproduct of phenylalanine metabolism, an essential amino acid that cannot be synthesized by the human body and must be obtained through dietary sources such as proteins.

In some rare genetic disorders, such as phenylketonuria (PKU), the body is unable to properly metabolize phenylalanine due to a deficiency or malfunction of the enzyme phenylalanine hydroxylase. As a result, phenylpyruvic acid and other toxic byproducts accumulate in the body, leading to various health problems such as intellectual disability, seizures, and behavioral issues.

Therefore, the medical relevance of phenylpyruvic acid lies in its association with certain metabolic disorders, particularly PKU, and its potential use as a diagnostic marker for these conditions.

Biopterin is a type of pteridine compound that acts as a cofactor in various biological reactions, particularly in the metabolism of amino acids such as phenylalanine and tyrosine. It plays a crucial role in the production of neurotransmitters like dopamine, serotonin, and noradrenaline. Biopterin exists in two major forms: tetrahydrobiopterin (BH4) and dihydrobiopterin (BH2). BH4 is the active form that participates in enzymatic reactions, while BH2 is an oxidized form that can be reduced back to BH4 by the action of dihydrobiopterin reductase.

Deficiencies in biopterin metabolism have been linked to several neurological disorders, including phenylketonuria (PKU), dopamine-responsive dystonia, and certain forms of autism. In these conditions, the impaired synthesis or recycling of biopterin can lead to reduced levels of neurotransmitters, causing various neurological symptoms.

Neonatal screening is a medical procedure in which specific tests are performed on newborn babies within the first few days of life to detect certain congenital or inherited disorders that are not otherwise clinically apparent at birth. These conditions, if left untreated, can lead to serious health problems, developmental delays, or even death.

The primary goal of neonatal screening is to identify affected infants early so that appropriate treatment and management can be initiated as soon as possible, thereby improving their overall prognosis and quality of life. Commonly screened conditions include phenylketonuria (PKU), congenital hypothyroidism, galactosemia, maple syrup urine disease, sickle cell disease, cystic fibrosis, and hearing loss, among others.

Neonatal screening typically involves collecting a small blood sample from the infant's heel (heel stick) or through a dried blood spot card, which is then analyzed using various biochemical, enzymatic, or genetic tests. In some cases, additional tests such as hearing screenings and pulse oximetry for critical congenital heart disease may also be performed.

It's important to note that neonatal screening is not a diagnostic tool but rather an initial step in identifying infants who may be at risk of certain conditions. Positive screening results should always be confirmed with additional diagnostic tests before any treatment decisions are made.

Anabaena variabilis is a species of cyanobacteria (blue-green algae) that can form filamentous colonies. It is capable of fixing atmospheric nitrogen, making it an important contributor to the nitrogen cycle in aquatic environments. The term 'variabilis' refers to the variable size and shape of its cells.

Here's a simple medical definition:

Anabaena variabilis: A species of filamentous cyanobacteria known for its ability to fix nitrogen, contributing to the nitrogen cycle in aquatic environments. Its cells can vary in size and shape.

Inborn errors of metabolism (IEM) refer to a group of genetic disorders caused by defects in enzymes or transporters that play a role in the body's metabolic processes. These disorders result in the accumulation or deficiency of specific chemicals within the body, which can lead to various clinical manifestations, such as developmental delay, intellectual disability, seizures, organ damage, and in some cases, death.

Examples of IEM include phenylketonuria (PKU), maple syrup urine disease (MSUD), galactosemia, and glycogen storage diseases, among many others. These disorders are typically inherited in an autosomal recessive manner, meaning that an affected individual has two copies of the mutated gene, one from each parent.

Early diagnosis and management of IEM are crucial to prevent or minimize complications and improve outcomes. Treatment options may include dietary modifications, supplementation with missing enzymes or cofactors, medication, and in some cases, stem cell transplantation or gene therapy.

Microcephaly is a medical condition where an individual has a smaller than average head size. The circumference of the head is significantly below the normal range for age and sex. This condition is typically caused by abnormal brain development, which can be due to genetic factors or environmental influences such as infections or exposure to harmful substances during pregnancy.

Microcephaly can be present at birth (congenital) or develop in the first few years of life. People with microcephaly often have intellectual disabilities, delayed development, and other neurological problems. However, the severity of these issues can vary widely, ranging from mild to severe. It is important to note that not all individuals with microcephaly will experience significant impairments or challenges.

A newborn infant is a baby who is within the first 28 days of life. This period is also referred to as the neonatal period. Newborns require specialized care and attention due to their immature bodily systems and increased vulnerability to various health issues. They are closely monitored for signs of well-being, growth, and development during this critical time.

Diet therapy is a medical treatment that involves using specific dietary modifications to manage or treat various medical conditions. This can include changing the types and amounts of food consumed, as well as adjusting the timing and frequency of meals. The goal of diet therapy is to provide the body with the necessary nutrients to support healing and maintain health while also addressing any specific dietary needs or restrictions related to a particular medical condition.

Diet therapy may be used to treat a wide range of conditions, including diabetes, heart disease, high blood pressure, obesity, food allergies and intolerances, gastrointestinal disorders, and kidney disease. For example, a person with diabetes may be placed on a diet that restricts sugar and simple carbohydrates to help manage their blood sugar levels, while a person with heart disease may be advised to follow a low-fat, high-fiber diet to reduce their risk of heart attack and stroke.

Diet therapy is often used in conjunction with other medical treatments, such as medication and surgery, and should be prescribed and monitored by a healthcare professional, such as a registered dietitian or a doctor who specializes in nutrition. It is important for individuals to follow their specific dietary recommendations closely in order to achieve the best possible outcomes.

I must clarify that I cannot provide a "medical definition" of intelligence, as intelligence is not a concept that is typically defined within the field of medicine. Intelligence is a term used to describe the ability to learn, understand, and make judgments or decisions based on reason, experience, and information. It is often measured through various cognitive abilities such as problem-solving, critical thinking, creativity, and knowledge acquisition.

The concept of intelligence is studied in many fields, including psychology, neuroscience, and education. In medicine, healthcare professionals may assess a person's cognitive abilities to better understand their health status or develop treatment plans. However, there is no specific "medical definition" for intelligence. Instead, it is a multifaceted concept that can be influenced by various genetic, environmental, and experiential factors.

Phenylalanine Ammonia-Lyase (PAL) is a enzyme that catalyzes the non-oxidative deamination of phenylalanine to trans-cinamic acid, releasing ammonia in the process. This reaction is a key step in the biosynthesis of various aromatic compounds in plants and microorganisms. In humans, PAL is not normally present, but its introduction through gene therapy has been studied as a potential treatment for phenylketonuria (PKU), a genetic disorder characterized by an inability to metabolize phenylalanine properly, leading to its accumulation in the body and potential neurological damage.

Homogentisic acid is not a medical condition, but rather an organic compound that plays a role in certain metabolic processes. It is a breakdown product of the amino acid tyrosine, and is normally further metabolized by the enzyme homogentisate 1,2-dioxygenase.

In some individuals, a genetic mutation can result in a deficiency of this enzyme, leading to a condition called alkaptonuria. In alkaptonuria, homogentisic acid accumulates in the body and can cause damage to connective tissues, joints, and other organs over time. Symptoms may include dark urine, arthritis, and pigmentation of the ears and eyes. However, it is important to note that alkaptonuria is a rare condition, affecting only about 1 in 250,000 people worldwide.

Congenital hypothyroidism is a medical condition characterized by the partial or complete absence of thyroid hormone production in the baby's body at birth. The thyroid gland, which is located in the front of the neck, produces hormones that are essential for normal growth and development of the brain and body.

Congenital hypothyroidism can occur due to various reasons such as the absence or abnormal development of the thyroid gland, or a defect in the production or regulation of thyroid hormones. In some cases, it may be caused by genetic mutations that affect the development or function of the thyroid gland.

If left untreated, congenital hypothyroidism can lead to mental and physical retardation, growth problems, and other health issues. Therefore, it is important to diagnose and treat this condition as early as possible, usually within the first few weeks of life. Treatment typically involves replacing the missing thyroid hormones with synthetic medications, which are safe and effective when administered under a doctor's supervision.

Intellectual disability (ID) is a term used when there are significant limitations in both intellectual functioning and adaptive behavior, which covers many everyday social and practical skills. This disability originates before the age of 18.

Intellectual functioning, also known as intelligence, refers to general mental capacity, such as learning, reasoning, problem-solving, and other cognitive skills. Adaptive behavior includes skills needed for day-to-day life, such as communication, self-care, social skills, safety judgement, and basic academic skills.

Intellectual disability is characterized by below-average intelligence or mental ability and a lack of skills necessary for day-to-day living. It can be mild, moderate, severe, or profound, depending on the degree of limitation in intellectual functioning and adaptive behavior.

It's important to note that people with intellectual disabilities have unique strengths and limitations, just like everyone else. With appropriate support and education, they can lead fulfilling lives and contribute to their communities in many ways.

A protein-restricted diet is a medical nutrition plan that limits the daily intake of protein. This type of diet may be recommended for individuals with certain kidney or liver disorders, as reducing protein intake can help decrease the workload on these organs and prevent further damage. The specific amount of protein restriction will depend on the individual's medical condition, overall health status, and prescribing healthcare professional's guidance.

It is essential to ensure that a protein-restricted diet is nutritionally adequate and balanced, providing sufficient calories, carbohydrates, fats, vitamins, and minerals. A registered dietitian or nutritionist should closely supervise the implementation of such a diet to prevent potential nutrient deficiencies and other related complications. In some cases, medical supplements may be necessary to meet the individual's nutritional requirements.

Individuals on a protein-restricted diet should avoid high-protein foods like meat, poultry, fish, eggs, dairy products, legumes, and nuts. Instead, they should focus on consuming low-protein or protein-free alternatives, such as fruits, vegetables, refined grains, and specific medical food products designed for individuals with special dietary needs.

It is crucial to consult a healthcare professional before starting any new diet, particularly one that restricts essential nutrients like protein. A healthcare provider can help determine if a protein-restricted diet is appropriate and ensure it is implemented safely and effectively.

Galactosemia is a rare metabolic disorder that affects the body's ability to metabolize the simple sugar galactose, which is found in milk and other dairy products. It is caused by deficiency or complete absence of one of the three enzymes needed to convert galactose into glucose:

1. Galactokinase (GALK) deficiency - also known as Galactokinase galactosemia, is a milder form of the disorder.
2. Galactose-1-phosphate uridylyltransferase (GALT) deficiency - the most common and severe form of classic galactosemia.
3. Galactose epimerase (GALE) deficiency - also known as Epimerase deficiency galactosemia, is a rare and milder form of the disorder.

The most severe form of the disorder, GALT deficiency, can lead to serious health problems such as cataracts, liver damage, mental retardation, and sepsis if left untreated. Treatment typically involves removing galactose from the diet, which requires avoiding all milk and dairy products. Early diagnosis and treatment are crucial for improving outcomes in individuals with galactosemia.

Tyrosine is an non-essential amino acid, which means that it can be synthesized by the human body from another amino acid called phenylalanine. Its name is derived from the Greek word "tyros," which means cheese, as it was first isolated from casein, a protein found in cheese.

Tyrosine plays a crucial role in the production of several important substances in the body, including neurotransmitters such as dopamine, norepinephrine, and epinephrine, which are involved in various physiological processes, including mood regulation, stress response, and cognitive functions. It also serves as a precursor to melanin, the pigment responsible for skin, hair, and eye color.

In addition, tyrosine is involved in the structure of proteins and is essential for normal growth and development. Some individuals may require tyrosine supplementation if they have a genetic disorder that affects tyrosine metabolism or if they are phenylketonurics (PKU), who cannot metabolize phenylalanine, which can lead to elevated tyrosine levels in the blood. However, it is important to consult with a healthcare professional before starting any supplementation regimen.

... exposure to mother Maternal malnutrition Maternal phenylketonuria Poorly controlled gestational diabetes Hyperthermia Maternal ... "Maternal phenylketonuria". Orphanet. Retrieved 2019-08-01. Reddy, Nihaal; Calloni, Sonia F.; Vernon, Hilary J.; Boltshauser, ...
ISBN 0-7817-3628-5. O'Flynn, Margaret E. (August 1967). "Diet Therapy in Phenylketonuria". Am. J. Nurs. 67 (8). doi:10.2307/ ... Pillitteri, Adele; Nettina, Sandra M. (2003). Maternal & Child Health Nursing (4th ed.). Hagerstwon, MD: Lippincott Williams & ... trademarked infant powder formula prescribed to replace milk in the diets of phenylketonuria sufferers in the infant and child ...
Rouse B, Azen C, Koch R, Matalon R, Hanley W, de la Cruz F, Trefz F, Friedman E, Shifrin H (1997). "Maternal phenylketonuria ... Lee PJ, Ridout D, Walter JH, Cockburn F (2005). "Maternal phenylketonuria: report from the United Kingdom Registry 1978-97". ... "Phenylketonuria (PKU)". Madriella Doula Network. Madriella Network. 14 October 2016. Retrieved 11 April 2021. "Phenylketonuria ... "Phenylketonuria". Merriam-Webster Dictionary. "Phenylketonuria". Lexico UK English Dictionary. Oxford University Press. ...
"Maternal PKU - Why I'm Having A Burrito Delivered To The Labour Ward". HuffPost UK. 2017-06-28. Retrieved 2018-11-20. "Happy ... The European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria (E.S.PKU) is a Europe-based non-profit ... It was founded in 1987 by patient-driven associations to help improve the treatment of phenylketonuria (PKU) in Europe. The E.S ... A member organization has to be a non-profit organization on a national level dealing with phenylketonuria patients. The E.S. ...
Lee PJ, Ridout D, Walter JH, Cockburn F (February 2005). "Maternal phenylketonuria: report from the United Kingdom Registry ... In the maternal form of PKU, excessive maternal phenylalanine can be absorbed by the fetus even if the fetus has not inherited ... March 1997). "Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early ... Maternal diabetes causes excessive birth size, making it harder for the infant to pass through the birth canal without injury ...
Other risk factors include maternal obesity, diabetes, rubella, indomethacin tocolysis, phenylketonuria, or elderly age. A link ... The Journal of Maternal-Fetal & Neonatal Medicine. 35 (25): 5400-5408. doi:10.1080/14767058.2021.1881475. PMID 33525939. S2CID ... Agricultural pesticides Solvents Landfill sites Heavy metals Maternal exposure to carbon monoxide from smoke (e.g. from ... between certain genes and maternal smoking has been shown to increase the chance of having children with congenital heart ...
Maternal and infant care and child labor were the Bureau's primary focus during its first two decades. However, other topics of ... The Children's Bureau provided early national leadership in the diagnosis and treatment of phenylketonuria (PKU) to prevent ... Maternal and Child Health Care funded clinics, professional education, and medical care for needy children. Crippled Children's ... The Children's Bureau's grant-in-aid programs grew significantly in the decade following World War II: In maternal and child ...
Effects of Untreated Maternal Phenylketonuria and Hyperphenylalaninemia on the fetus. New England Journal of Medicine 1983;309: ... Maternal Phenylketonuria and Hyperphenylalaninemia. An International Survey of the Outcome of Untreated and Treated Pregnancies ... Levy is also renowned for clinical research in phenylketonuria (PKU), including bringing international attention to maternal ... phenylketonuria (PKU), and maternal PKU. Levy has published over 400 papers on biochemical genetic disorders and newborn ...
"Maternal phenylketonuria syndrome in cousins caused by mild, unrecognized phenylketonuria in their mothers homozygous for the ...
... maternal phenylketonuria, and birth asphyxia. MCPH has an incidence rate of 1/30,000 to 1/250,000 in western populations. To ...
Administration during pregnancy is not recommended because sodium phenylbutyrate treatment could mimic maternal phenylketonuria ...
... and maternal illness (diabetes mellitus, phenylketonuria, and systemic lupus erythematosus). Alcohol exposure in the father ... Additionally, as maternal obesity increases, the risk of heart defects also increases. A distinct physiological mechanism has ... Mills JL, Troendle J, Conley MR, Carter T, Druschel CM (June 2010). "Maternal obesity and congenital heart defects: a ... not been identified to explain the link between maternal obesity and CHD, but both pre-pregnancy folate deficiency and diabetes ...
Yang J, Jiang Z, Wang Y, Qureshi IA, Wu XD (1997-04-01). "Maternal-fetal transfer of metallic mercury via the placenta and milk ... Cretinism Diabetes mellitus Folic acid deficiency Hyperthermia Phenylketonuria Rheumatic disorder Klaassen, Curtis (1975). ... Because of the complexity of the embryo-fetal development, including the maternal-fetal interactions during gestation, it is ... More factors causing developmental toxicity are radiation, infections (e.g. rubella), maternal metabolic imbalances (e.g. ...
... virus Prolonged maternal fever in the first trimester Exposure to anticonvulsants or alcohol Untreated maternal phenylketonuria ...
... phenylketonurias MeSH C10.228.140.163.100.687.500 - phenylketonuria, maternal MeSH C10.228.140.163.100.725 - pyruvate ...
... phenylketonurias MeSH C18.452.648.066.766.500 - phenylketonuria, maternal MeSH C18.452.648.066.880 - tyrosinemias MeSH C18.452. ... phenylketonurias MeSH C18.452.100.100.687.500 - phenylketonuria, maternal MeSH C18.452.100.100.725 - pyruvate carboxylase ... phenylketonurias MeSH C18.452.648.151.687.500 - phenylketonuria, maternal MeSH C18.452.648.151.725 - pyruvate carboxylase ...
... phenylketonurias MeSH C16.320.565.066.766.500 - phenylketonuria, maternal MeSH C16.320.565.066.880 - tyrosinemias MeSH C16.320. ... phenylketonurias MeSH C16.320.565.150.687.500 - phenylketonuria, maternal MeSH C16.320.565.150.725 - pyruvate carboxylase ...
If the mother has the PKU genotype but has been treated so as to be asymptomatic, high levels of [phe] in the maternal blood ... Phenylketonuria (PKU) can result in severe hyperphenylalaninemia. Phenylalanine concentrations are routinely screened in ... Treatment for life is recommended to reduce the risk of long term neuropsychiatric problems and reduce the risk of maternal PKU ... Some cases in adult women have been detected using maternal screening programs or following birth of children with birth ...
The maternal ancestral lineages of Arabic countries are very diverse. The original and still most prevalent maternal ... Interventions after birth, including: newborn biochemical screening for congenital hypothyroidism, phenylketonuria (PKU), ... as seen most in greater Syria Iraq and Egypt that have extra maternal haplogroups than the Middle East- associated maternal ( ... knowing the ancestral Y paternal and mitochondrial maternal haplogroups and other private companies Nuclear DNA might give ...
1966 Treatment of phenylketonuria : Report to the Medical Research Council of the conference on phenylketonuria. Alan A. ... He acted on the expert advisory panel on maternal and child health panel. of the World Health Organization As a member of the ... and in continuing his work on phenylketonuria, until he suffered a stroke in 1968 and has to drastically reduce is working ...
Non-invasive techniques include examinations of the woman's womb through ultrasonography or maternal serum screens. These non- ... all US states currently test infants for phenylketonuria and congenital hypothyroidism. US state law mandates collecting a ...
Sajantila A, Salem AH, Savolainen P, Bauer K, Gierig C, Pääbo S (October 1996). "Paternal and maternal DNA lineages reveal a ... These include cystic fibrosis and phenylketonuria. In Finland, about 1 in 80 persons are carriers of a cystic fibrosis mutation ...
Fragile X syndrome Sickle cell disease Phenylketonuria (PKU) Haemophilia The description of a mode of biological inheritance ... Inheritance through the maternal line (in case of mitochondrial DNA loci) Inheritance through the paternal line (in case of Y- ... Maternal or paternal imprinting phenomena (also see epigenetics) 5. Sex-linked interactions Sex-linked inheritance (gonosomal ...
For example, if a screening test during a pregnancy (such as maternal blood screening or ultrasound) reveals a risk of a health ... such as phenylketonuria). Genetic tests are available for a number of genetic conditions, including but not limited to: Down ... severe male factor or advanced maternal age. Finally, PGT seems to be: safe for the embryo, trustable in the diagnosis, more ...
It may also refer to the effects of increased maternal or parental investment in caring for disadvantaged offspring, seeking to ... and phenylketonuria among persons from Ireland.[citation needed] Levin, BR (1967). "The effect of reproductive compensation on ...
... function Mapping population Marfan syndrome Marker Marker retention Mass spectrometry Mate-killer Maternal effect Maternal ... Phe Phenocopy Phenotype Phenotypic variance Phenylketonuria Pheromone Phosphodiester bond Photoreactivation Phyletic evolution ...
This type of inheritance, also known as maternal inheritance, is the rarest and applies to the 13 genes encoded by ... Woolf, LI (1986). "The heterozygote advantage in phenylketonuria". American Journal of Human Genetics. 38 (5): 773-5. PMC ... Such disorders include cystic fibrosis, sickle cell disease, phenylketonuria and thalassaemia. Hereditary defects in enzymes ...
Phenylketonuria (PKU) was the first disorder targeted for newborn screening, being implemented in a small number of hospitals ... as some maternal conditions can be identified through results on the baby's newborn screen. Depending on the likelihood of the ... Robert Guthrie is given much of the credit for pioneering the earliest screening for phenylketonuria in the late 1960s using a ... NBS started with the discovery that the amino acid disorder phenylketonuria (PKU) could be treated by dietary adjustment, and ...
Referral for counseling in a prenatal genetics clinic to discuss risks to the pregnancy (advanced maternal age, teratogen ... phenylketonuria (PKU), maple syrup urine disease, organic acidurias and urea cycle disorders. Such restrictive diets can be ... phenylketonuria, and urea cycle disorders. Cytogenetics is the study of chromosomes and chromosome abnormalities. While ... the newborn screen incorporates biochemical tests to screen for treatable conditions such as galactosemia and phenylketonuria ( ...
For example, advanced maternal age, maternal obesity, maternal type 2 diabetes and maternal hypertension all increase the risk ... Selected metabolic conditions which may (rarely) be associated with an ASD appearance are: Phenylketonuria (untreated) ... Maternal diagnoses of polycystic ovary syndrome was found to associated with higher risk of autism. Maternal obesity during ... The known maternal risk factors for autism diagnosis in her offspring are similar to the risk factors for sleep apnea. ...
Diseases: Maternal Phenylketonuria (PKU) Maternal Phenylketonuria (PKU). David Warmflash July 6, 2022 ...
Maternal phenylketonuria: Report from the United Kingdom Registry 1978-97. Archives of Disease in Childhood 90: 143-146. ... Maternal phenylketonuria collaborative study (MPKUCS) offspring: Facial anomalies, malformations, and early neurological ... The neurochemistry of phenylketonuria. European Journal of Pediatrics 169: S109-113.. Credits. New World Encyclopedia writers ... Phenylketonuria. From New World Encyclopedia. Revision as of 20:31, 21 December 2015 by Jennifer Tanabe. (talk , contribs) (→‎ ...
Phenylketonuria (PKU), the most common inborn error of amino acid metabolism, results from an impaired ability to metabolize ... Does maternal knowledge and parent education affect blood phenylalanine control in phenylketonuria?. J Hum Nutr Diet. 2008 Aug ... Lee PJ, Ridout D, Walter JH, Cockburn F. Maternal phenylketonuria: report from the United Kingdom Registry 1978-97. Arch Dis ... encoded search term (Phenylketonuria (PKU)) and Phenylketonuria (PKU) What to Read Next on Medscape ...
Maternal phenylketonuria (PKU) effects answers are found in the 5-Minute Pediatric Consult powered by Unbound Medicine. ... "Maternal Phenylketonuria (PKU) Effects." 5-Minute Pediatric Consult, 8th ed., Wolters Kluwer, 2019. Pediatrics Central, peds. ... Maternal phenylketonuria (PKU) effects. (2019). In Cabana, M. D. (Ed.), 5-Minute Pediatric Consult (8th ed.). Wolters Kluwer. ... Maternal Phenylketonuria (PKU) Effects [Internet]. In: Cabana MDM, editors. 5-Minute Pediatric Consult. Wolters Kluwer; 2019. [ ...
... exposure to mother Maternal malnutrition Maternal phenylketonuria Poorly controlled gestational diabetes Hyperthermia Maternal ... "Maternal phenylketonuria". Orphanet. Retrieved 2019-08-01. Reddy, Nihaal; Calloni, Sonia F.; Vernon, Hilary J.; Boltshauser, ...
The international collaborative study of maternal phenylketonuria: Status report 1998. R. Koch, E. Friedman, C. Azen, W. Hanley ... Dive into the research topics of The international collaborative study of maternal phenylketonuria: Status report 1998. ...
Abnormal findings in maternal phenylketonuria. Together they form a unique fingerprint. * Maternal Phenylketonuria Medicine & ... Developmental changes in amino acid concentrations in human amniotic fluid: Abnormal findings in maternal phenylketonuria. / ... Developmental changes in amino acid concentrations in human amniotic fluid : Abnormal findings in maternal phenylketonuria. In ... Developmental changes in amino acid concentrations in human amniotic fluid: Abnormal findings in maternal phenylketonuria. ...
Prenatal trauma to the brain, such as maternal alcohol abuse, and postnatal trauma, such as hypoxia, are potential causes of ... Maternal phenylketonuria. Normal variation. Structural brain defects. Universal craniosynostosis. Craniosynostosis is the ...
Pozharny is board certified in Maternal & Fetal Medicine. ... Yevgeniya Pozharny, MD is a maternal-fetal medicine specialist ... Phenylketonuria Screening ... a Maternal-Fetal Medicine Specialist. in Brooklyn, NY. Show ... Compare with other Maternal-Fetal Medicine Specialists. Compare Dr. Pozharny with Maternal-Fetal Medicine Specialists near you ... a Maternal-Fetal Medicine Specialist. in Brooklyn, NY and has 20 years experience. They graduated from G WASHINGTON UNIV SCH ...
Kunz is board certified in Maternal & Fetal Medicine. ... Liza Kunz, MD is a maternal-fetal medicine specialist in ... Phenylketonuria Screening ... a Maternal-Fetal Medicine Specialist. in Mountain View, CA. ... a Maternal-Fetal Medicine Specialist. in Mountain View, CA and has 23 years experience. They graduated from STATE UNIVERSITY OF ... Liza Kunz, MD is a maternal-fetal medicine specialist in Mountain View, CA and has over 22 years of experience in the medical ...
Psychosocial factors in maternal phenylketonuria: prevention of unplanned pregnancies. Am J Public Health 1991 Mar;81(3):299- ... St.James, P.S., Shapiro, E., and Waisbren, S.E. (1999). The resource mothers program for maternal phenylketonuria. Am J Pub ... Brenton, D.P., Lilburn, M. Maternal phenylketonuria: A study from the United Kingdom. Eur J Pediatr 1996; 155[Suppl 1]: S177- ... Fisch, R.O., Burke, B., Bass, J., Ferrara, T.B., and Mastri A. (1986). Maternal phenylketonuria - Chronology of the detrimental ...
Maternal conditions:. *Pregestational diabetes. *Phenylketonuria. *Autoimmune disease: SSA/SSB positive antibodies. *In vitro ...
Categories: Phenylketonuria, Maternal Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
Phenylketonuria; maternal phenylketonuria; maple syrup urine disease; tyrosinemia; homocystinuria; histidinemia; urea cycle ... Phenylketonuria; maternal phenylketonuria; maple syrup urine disease; tyrosinemia; homocystinuria; histidinemia; urea cycle ... b) One dollar ($1) of which shall be used by the Division of Maternal and Child Health to pay for therapeutic food, formulas, ...
This study explores the management and outcomes of planned, full-term pregnancies in patients with phenylketonuria (PKU). ... Koch R, Hanley W, Levy H, Matalon K, Matalon R, Rouse B, et al (2003). The maternal phenylketonuria international study: 1984- ... Shen M (2016). Paying more attention to the prevention and treatment of maternal phenylketonuria. Chin J Appl Clin Pediatr31(20 ... Aldámiz-Echevarría L, Couce ML, Llarena M, Andrade F (2014). A new case of maternal phenylketonuria treated with ...
i,Methods,/i,. 86 children with phenylketonuria (PKU) diagnosed and treated in our hospital from February 2019 to September ... To explore and analyze the influencing factors of tetrahydrobiopterin therapy in patients with phenylketonuria. , ... ③ this study was approved by the Ethics Committee of Hebei Shijiazhuang Maternal and Child Health Care Hospital, under No. SJZ8 ... Influencing Factors on the Use of Tetrahydrobiopterin in Patients with Phenylketonuria. Hui Gao. 1 ...
Research has also linked autism to untreated phenylketonuria (also called PKU, a metabolic disorder caused by the absence of an ... Other risk factors include maternal metabolic conditions such as diabetes and obesity. ...
Later she worked with maternal phenylketonuria patients, reintroducing the phenylketonuria diet during pregnancy. ... Dr Tischler had a special interest in phenylketonuria and was instrumental in instituting the Guthrie test, which is the ... She also helped develop a diet to treat newborns diagnosed with phenylketonuria, which allowed patients to develop normally. ...
Phenylketonuria (PKU) - Learn about the causes, symptoms, diagnosis & treatment from the MSD Manuals - Medical Consumer Version ... This condition is called maternal PKU.. Prevention and Treatment of PKU *. Phenylalanine-restricted diet ... Phenylketonuria is usually diagnosed with a routine newborn screening test Newborn Screening Tests Screening tests are done to ... Phenylketonuria is a disorder of amino acid metabolism Overview of Amino Acid Metabolism Disorders Amino acid metabolism ...
Congenital rubella syndrome due to infection after maternal antibody conversion with vaccine. Jpn J Infect Dis. 2003;56:68-9. ... the prevalence of infectious diseases is higher than phenylketonuria (1 in 13,000) and congenital hypothyroidism (1 in 3,500). ... In 15 neonates, having only IgG antibodies in the serum was interpreted as being of maternal origin by the clinicians. The lack ... In 19 cases, the infants IgG levels were interpreted by the pediatrician as being of maternal origin and were not followed. ...
Maternal Health Obstetrics Obstetrics - High Risk Obstetrics - Post-Partum Obstetrics - Prenatal Pregnancy - Counseling ... Phenylketonuria Pulmonary (Pediatric) Regional Development Rheumatic Heart Rheumatology/Arthritis (Pediatric) Scoliosis (Child ...
The second chapter is a qualitative study exploring the emotional impact of Phenylketonuria (PKU) in pregnancy and how this ... Harris, Charlotte Ruth (2021). Maternal perinatal mental health: effects on children. University of Birmingham. Clin.Psy.D. ... The first chapter is a systematic review examining the relationship between post-natal maternal anxiety and child somatic, ... affects the developing maternal-infant relationship. The third chapter is a press briefing document, which provides accessible ...
... and other maternal illnesses including diabetes and phenylketonuria. Although researchers are examining risk factors that may ...
... phenylketonuria and hemoglobinopathies. ... Maternal, Infant, and Child Health. Fetal, Infant, Child, and ... Data are reported by States each year as part of the Maternal and Child Health Block Grant application. A national weighted ... 2. Heck, K.E., and Klein, R.J. Operational definitions for year 2000 objectives: Priority area 14, Maternal and Infant Health. ... NCHS uses the definition of maternal mortality and related coding conventions recommended in the ICD-9 by the World Health ...
Nutritions taken during pregnancy can have significant and lasting effects on maternal and newborn health. If associated with ... Maternal Phenylketonuria (PKU). Increased phenylalanine levels are toxic and teratogenic to the developing fetus. Spontaneous ... Roles of Adverse Maternal Conditions in Congenital Anomalies BeneficialPlant 26/08/2023. 28/01/2023. ... If maternal zinc deficiency is short-lived, cell cycle may not be adversely affected. Zinc deficiency results in increased ...
Maternal Phenylketonuria (PKU). David Warmflash July 6, 2022 Multiple Sclerosis and Breastfeeding. Kristen Hollinger February ... These maternal blood vessels typically change shape and grow wider to provide increasing amounts of nutrients to the developing ... When the embryo first invades the uterus lining, it receives nutrients from maternal blood vessels via root-like growths called ...
Metabolic disorders, including phenylketonuria (PKU). *Trauma to the brain, which may occur due to the use of forceps or a ... For example, certain maternal infections during pregnancy are associated with developmental delays. If a treating physician ...
... maternal rubella infection, phenylketonuria, hypertension, and diabetes, studies investigating most of environmental risk ... In some cases, there may be maternal or fetal indications to anticipate delivery, including a variety of obstetric ones. Thus, ... Aside from some cardiac teratogens and prenatal maternal conditions or exposures associated with an increased risk for CHD, ... Information regarding parental characteristics and conditions, maternal therapeutic drug exposures, parental nontherapeutic ...

No FAQ available that match "phenylketonuria maternal"

No images available that match "phenylketonuria maternal"